INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 194,854 | -- | -- |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | $20.32 | 697,000 |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 673
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | -- | -- |
| Dec 18, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 195,079 | -- | 195,079 |
| Dec 13, 2017 |
Director, President & CSO
Trans History: 673
|
Director, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | $21.92 | 786,786 |
| Dec 13, 2017 |
Director, President & CSO
Trans History: 673
|
Director, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | -- | -- |
| Dec 17, 2007 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 195,438 | -- | 195,438 |
| Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
Trans History: 673
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 196,430 | $28.01 | 1,066,135 |
| Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
Trans History: 673
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 196,430 | -- | -- |
| Aug 18, 2021 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 200,000 | $650.03 | 304,746 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.